Advertisement
Cinco consejos para dejar de fumar en 2021

USPSTF Affirms Evidence-Based Methods for Smoking Cessation

0

Behavioral and pharmacotherapy interventions, alone or in combination, recommended; evidence insufficient for e-cigarettes

HealthDay Reports: Most Americans

California First State With Over 3 Million COVID-19 Cases

0

Biden administration has said it will not be lifting restrictions on international travel

La vacuna de Pfizer contra la COVID parece promisoria

One-Third of U.S. Adults Likely to Refuse a COVID-19 Vaccine

0

Blacks, women, and conservatives more hesitant in the United States

Stopping RAS Inhibitors May Worsen Outcomes in CKD

0

Stopping therapy tied to lower risk for dialysis, but higher risk for cardiovascular events and death

HealthDay Reports: COVID-19 Roundup for the Week of June 29-July 3

Physician’s Briefing Weekly Coronavirus Roundup

0
Here is what the editors at Physician's Briefing chose as the most important COVID-19 developments for you and your practice for the week of...
更年期症状が多いほど仕事のパフォーマンスが低下?

Primary Care-Recorded Mental Illness Decreased During COVID-19

0

Reductions seen in incidence of primary care-recorded depression, anxiety disorders, first antidepressant prescribing in United Kingdom

Triplet Therapy Slows Refractory Multiple Myeloma

Bupropion-Naltrexone Bests Placebo in Methamphetamine Use Disorder

0

Response was low but higher with naltrexone-bupropion than placebo during 12-week, two-stage trial

One-Dose Covid-19 Vaccine From Johnson & Johnson Looks Promising

U.S. COVID-19 Vaccine Rollout Nears 1 Million Doses Per Day

0

News comes as Ohio State University researchers discover new variant of COVID-19 virus

Lorlatinib Superior to Crizotinib for ALK-Positive NSCLC

Inhaled Treprostinil Beneficial in Pulmonary Hypertension

0

Exercise capacity improved, clinical worsening reduced for patients with pulmonary HTN due to interstitial lung disease

La vacuna de Pfizer contra la COVID parece promisoria

Ad26.COV2-S Vaccine Seems Safe, Immunogenic for SARS-CoV-2

0

Neutralizing antibodies detected in 90 percent or more of all participants on day 29 after the first vaccine dose